Company / Cost of Revenue
RECURSION PHARMACEUTICALS, INC. Cost of Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$71.0M
FY2025
5-year range
$0 / $71.0M
FY2021-FY2025
Trend
+56.8%
vs FY2024
Sector context
#52 of 85
Health Care
What the data says
At $71M, RECURSION PHARMACEUTICALS, INC.'s cost of revenue ranks #34 of 85 in the Health Care sector. Cost of Revenue has increased for 3 consecutive years, from $0 in FY2022 to $71M in FY2025.
Based on SEC 10-K filings.
$71M in FY2025.
Increased from $43M to $71M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#34 of 85 in Health CareTop 39% of 85This company $71.0M Sector average $2.0B
▼
-96.4% below sector average
Key checks
Key Insights
- In FY2025, cost of revenue increased 56.8% year-over-year.
- Ranks #52 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $71.0M | +56.8% |
| FY2024 | $45.2M | +6.2% |
| FY2023 | $42.6M | - |
| FY2022 | $0 | - |
| FY2021 | $0 | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026